| Literature DB >> 35671112 |
Ravi Dhital1, Shashi Anand2, Brianna Graber1, Qiang Zeng3, Victoria M Velazquez1, Srinivasa R Boddeda1, James R Fitch4, Ranjana W Minz2, Mukut Minz5, Ashish Sharma5, Rachel Cianciolo6, Masako Shimamura1,7.
Abstract
Human cytomegalovirus (HCMV) infection is associated with renal allograft failure. Allograft damage in animal models is accelerated by CMV-induced T helper 17 (Th17) cell infiltrates. However, the mechanisms whereby CMV promotes Th17 cell-mediated pathological organ inflammation are uncharacterized. Here we demonstrate that murine CMV (MCMV)-induced intragraft Th17 cells have a Th1/17 phenotype co-expressing IFN-γ and/or TNF-α, but only a minority of these cells are MCMV specific. Instead, MCMV promotes intragraft expression of CCL20 and CXCL10, which are associated with recruitment of CCR6+ CXCR3+ Th17 cells. MCMV also enhances Th17 cell infiltrates after ischemia-reperfusion injury, independent of allogeneic responses. Pharmacologic inhibition of the Th17 cell signature cytokine, IL-17A, ameliorates MCMV-associated allograft damage without increasing intragraft viral loads or reducing MCMV-specific Th1 cell infiltrates. Clinically, HCMV DNAemia is associated with higher serum IL-17A among renal transplant patients with acute rejection, linking HCMV reactivation with Th17 cell cytokine expression. In summary, CMV promotes allograft damage via cytokine-mediated Th1/17 cell recruitment, which may be pharmacologically targeted to mitigate graft injury while preserving antiviral T cell immunity.Entities:
Keywords: basic (laboratory) research/science; chemokines/chemokine receptors; clinical research/practice; infection and infectious agents-viral: cytomegalovirus (CMV); kidney transplantation/nephrology; rejection: acute, cytokines/cytokine receptors
Mesh:
Substances:
Year: 2022 PMID: 35671112 PMCID: PMC9547825 DOI: 10.1111/ajt.17116
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 9.369